Bulk Manufacturer of Controlled Substances Application: Chattem Chemicals, 56103-56104 [2018-24485]

Download as PDF 56103 Federal Register / Vol. 83, No. 218 / Friday, November 9, 2018 / Notices On March 27, 2012, 3D PDF filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on April 20, 2012 (77 FR 23754). The last notification was filed with the Department on August 15, 2018. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on September 4, 2018 (83 FR 44904). Suzanne Morris, Chief, Premerger and Division Statistics Unit, Antitrust Division. [FR Doc. 2018–24542 Filed 11–8–18; 8:45 am] BILLING CODE 4410–11–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Bulk Manufacturer of Controlled Substances Registration ACTION: Notice of registration. The registrant listed below has applied for and been granted registration by the Drug Enforcement Administration (DEA) as a bulk manufacturer of various classes of schedule I and II controlled substances. SUPPLEMENTARY INFORMATION: The company listed below applied to be registered as bulk manufacturer of various basic classes of controlled substances. Information on the previously published notice is listed in the table below. No comments or objections were submitted for this notice. SUMMARY: Company FR citation Euticals Inc ... 83 FR 39129 Published August 8, 2018. The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of this registrant to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company’s maintenance of effective controls against diversion by inspecting and testing the company’s physical security systems, verifying the company’s compliance with state and local laws, and reviewing the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a registration as a bulk manufacturer to the above listed company. Dated: October 29, 2018. John J. Martin, Assistant Administrator. [FR Doc. 2018–24484 Filed 11–8–18; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Bulk Manufacturer of Controlled Substances Application: Chattem Chemicals ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before January 8, 2019. DATES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. ADDRESSES: SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.33(a), this is notice that on August 2, 2018, Chattem Chemicals, 3801 Saint Elmo Avenue, Chattanooga, Tennessee 37409–1237 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances: khammond on DSK30JT082PROD with NOTICES Controlled substance Drug code Gamma Hydroxybutyric Acid ................................................................................................................................... Marihuana ................................................................................................................................................................ Tetrahydrocannabinols ............................................................................................................................................ 4-Methoxyamphetamine .......................................................................................................................................... Dihydromorphine ..................................................................................................................................................... Amphetamine .......................................................................................................................................................... Methamphetamine ................................................................................................................................................... Lisdexamfetamine ................................................................................................................................................... Methylphenidate ...................................................................................................................................................... Codeine ................................................................................................................................................................... Dihydrocodeine ........................................................................................................................................................ Oxycodone .............................................................................................................................................................. Hydromorphone ....................................................................................................................................................... Hydrocodone ........................................................................................................................................................... Levorphanol ............................................................................................................................................................. Methadone ............................................................................................................................................................... Methadone intermediate .......................................................................................................................................... Morphine .................................................................................................................................................................. Oripavine ................................................................................................................................................................. Thebaine .................................................................................................................................................................. Oxymorphone .......................................................................................................................................................... Noroxymorphone ..................................................................................................................................................... VerDate Sep<11>2014 17:36 Nov 08, 2018 Jkt 247001 PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 E:\FR\FM\09NON1.SGM 09NON1 2010 7360 7370 7411 9145 1100 1105 1205 1724 9050 9120 9143 9150 9193 9220 9250 9254 9300 9330 9333 9652 9668 Schedule I I I I I II II II II II II II II II II II II II II II II II 56104 Federal Register / Vol. 83, No. 218 / Friday, November 9, 2018 / Notices Controlled substance Drug code Tapentadol ............................................................................................................................................................... Fentanyl ................................................................................................................................................................... The company plans to manufacture the listed controlled substances in bulk for distribution and sale to its customers. In reference to drug code 7360 (marihuana) and 7370 (tetrahydrocannabinols) the company plans to bulk manufacture these drugs as synthetic. No other activities for these drug codes are authorized for this registration. Dated: October 25, 2018. John J. Martin, Assistant Administrator. [FR Doc. 2018–24485 Filed 11–8–18; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE [OMB Number 1105–0025] Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension Without Change, of a Previously Approved Collection; Federal Coal Lease Request Antitrust Division, Department of Justice. ACTION: 30-Day notice. AGENCY: The Department of Justice (DOJ), Antitrust Division (ATR), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. DATES: Comments are encouraged and will be accepted for 30 days until December 10, 2018. FOR FURTHER INFORMATION CONTACT: If you have additional comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Jill Ptacek, Attorney, Antitrust Division, United States Department of Justice, 450 Fifth Street NW, Suite 8000, Washington, DC 20530 (phone: 202– 307–6607). SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should khammond on DSK30JT082PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:36 Nov 08, 2018 Jkt 247001 address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Evaluate whether and if so how the quality, utility, and clarity of the information to be collected can be enhanced; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. Overview of This Information Collection 1. Type of Information Collection: Extension of a currently approved collection. 2. The Title of the Form/Collection: Federal Coal Lease Reserves. 3. The agency form number, if any, and the applicable component of the Department sponsoring the collection: The form numbers are ATR–139 and ATR–140. The applicable component within the Department of Justice is the Antitrust Division. 4. Affected public who will be asked or required to respond, as well as a brief abstract: Primary: Business or other for profit. Other: None. The Department of Justice evaluates the competitive impact of issuances, transfers and exchanges of federal coal leases. These forms seek information regarding a prospective coal lessee’s existing coal reserves. The Department uses this information to determine whether the issuance, transfer or exchange of the federal coal lease is consistent with the antitrust laws. 5. An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: It is estimated that 10 respondents will complete each form, PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 9780 9801 Schedule II II with each response taking approximately two hours. 6. An estimate of the total public burden (in hours) associated with the collection: There are an estimated 20 annual burden hours associated with this collection, in total. If additional information is required contact: Melody Braswell, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Two Constitution Square, 145 N Street NE, Suite 3E.405B, Washington, DC 20530. Dated: November 6, 2018. Melody Braswell, Department Clearance Officer, PRA, U.S. Department of Justice. [FR Doc. 2018–24544 Filed 11–8–18; 8:45 am] BILLING CODE 4410–12–P DEPARTMENT OF JUSTICE Notice of Lodging of Proposed Consent Decree Under the Clean Water Act On October 31, 2018, the Department of Justice lodged a proposed Consent Decree with the United States District Court for the Western District of Louisiana in the lawsuit entitled United States and Louisiana Department of Environmental Quality v. Evangeline Enterprises LLC, Civil Action No. 17– 01340. In this action, the United States, on behalf of the U.S. Environmental Protection Agency, together with the Louisiana Department of Environmental Quality (‘‘LDEQ’’), sought penalties and injunctive relief under the Clean Water Act and the Louisiana Environmental Quality Act against Evangeline Enterprises LLC (‘‘Evangeline’’) for continuous unauthorized discharges of pollutants from Evangeline’s race horse training facility in Carencro, Louisiana to waters of the United States and waters of the State of Louisiana. The proposed Consent Decree will resolve the claims alleged by the United States and LDEQ and requires Evangeline to pay $300,000 in civil penalties and perform injunctive relief to bring its facility into compliance with applicable federal and state laws and regulations to prevent future discharges to area waterways. E:\FR\FM\09NON1.SGM 09NON1

Agencies

[Federal Register Volume 83, Number 218 (Friday, November 9, 2018)]
[Notices]
[Pages 56103-56104]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-24485]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Bulk Manufacturer of Controlled Substances Application: Chattem 
Chemicals

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration on or before January 8, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: 
    The Attorney General has delegated his authority under the 
Controlled Substances Act to the Administrator of the Drug Enforcement 
Administration (DEA), 28 CFR 0.100(b). Authority to exercise all 
necessary functions with respect to the promulgation and implementation 
of 21 CFR part 1301, incident to the registration of manufacturers, 
distributors, dispensers, importers, and exporters of controlled 
substances (other than final orders in connection with suspension, 
denial, or revocation of registration) has been redelegated to the 
Assistant Administrator of the DEA Diversion Control Division 
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, 
appendix to subpart R.
    In accordance with 21 CFR 1301.33(a), this is notice that on August 
2, 2018, Chattem Chemicals, 3801 Saint Elmo Avenue, Chattanooga, 
Tennessee 37409-1237 applied to be registered as a bulk manufacturer of 
the following basic classes of controlled substances:

 
------------------------------------------------------------------------
      Controlled substance           Drug code           Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid.......            2010  I
Marihuana.......................            7360  I
Tetrahydrocannabinols...........            7370  I
4-Methoxyamphetamine............            7411  I
Dihydromorphine.................            9145  I
Amphetamine.....................            1100  II
Methamphetamine.................            1105  II
Lisdexamfetamine................            1205  II
Methylphenidate.................            1724  II
Codeine.........................            9050  II
Dihydrocodeine..................            9120  II
Oxycodone.......................            9143  II
Hydromorphone...................            9150  II
Hydrocodone.....................            9193  II
Levorphanol.....................            9220  II
Methadone.......................            9250  II
Methadone intermediate..........            9254  II
Morphine........................            9300  II
Oripavine.......................            9330  II
Thebaine........................            9333  II
Oxymorphone.....................            9652  II
Noroxymorphone..................            9668  II

[[Page 56104]]

 
Tapentadol......................            9780  II
Fentanyl........................            9801  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution and sale to its customers.
    In reference to drug code 7360 (marihuana) and 7370 
(tetrahydrocannabinols) the company plans to bulk manufacture these 
drugs as synthetic. No other activities for these drug codes are 
authorized for this registration.

    Dated: October 25, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-24485 Filed 11-8-18; 8:45 am]
 BILLING CODE 4410-09-P